Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism

  • Meyer G
  • Vicaut E
  • Danays T
  • et al.
1.3kCitations
Citations of this article
1.5kReaders
Mendeley users who have this article in their library.

Abstract

BACKGROUND The role of fibrinolytic therapy in patients with intermediate-risk pulmonary embolism is controversial. METHODS In a randomized, double-blind trial, we compared tenecteplase plus heparin with placebo plus heparin in normotensive patients with intermediate-risk pulmonary embolism. Eligible patients had right ventricular dysfunction on echocardiography or computed tomography, as well as myocardial injury as indicated by a positive test for cardiac troponin I or troponin T. The primary outcome was death or hemodynamic decompensation (or collapse) within 7 days after randomization. The main safety outcomes were major extracranial bleeding and ischemic or hemorrhagic stroke within 7 days after randomization. RESULTS Of 1006 patients who underwent randomization, 1005 were included in the intention-to-treat analysis. Death or hemodynamic decompensation occurred in 13 of 506 patients (2.6%) in the tenecteplase group as compared with 28 of 499 (5.6%) in the placebo group (odds ratio, 0.44; 95% confidence interval, 0.23 to 0.87; P=0.02). Between randomization and day 7, a total of 6 patients (1.2%) in the tenecteplase group and 9 (1.8%) in the placebo group died (P=0.42). Extracranial bleeding occurred in 32 patients (6.3%) in the tenecteplase group and 6 patients (1.2%) in the placebo group (P<0.001). Stroke occurred in 12 patients (2.4%) in the tenecteplase group and was hemorrhagic in 10 patients; 1 patient (0.2%) in the placebo group had a stroke, which was hemorrhagic (P=0.003). By day 30, a total of 12 patients (2.4%) in the tenecteplase group and 16 patients (3.2%) in the placebo group had died (P=0.42). CONCLUSIONS In patients with intermediate-risk pulmonary embolism, fibrinolytic therapy prevented hemodynamic decompensation but increased the risk of major hemorrhage and stroke. (Funded by the Programme Hospitalier de Recherche Clinique in France and others; PEITHO EudraCT number, 2006-005328-18; ClinicalTrials.gov number, NCT00639743.).

References Powered by Scopus

Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients

4112Citations
N/AReaders
Get full text

Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical practice guidelines

3310Citations
N/AReaders
Get full text

Acute pulmonary embolism: Clinical outcomes in the International Cooperative Pulmonary Embolism Registry (ICOPER)

2581Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report

4058Citations
N/AReaders
Get full text

2019 ESC Guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European respiratory society (ERS)

3015Citations
N/AReaders
Get full text

2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism

2488Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Meyer, G., Vicaut, E., Danays, T., Agnelli, G., Becattini, C., Beyer-Westendorf, J., … Konstantinides, S. V. (2014). Fibrinolysis for Patients with Intermediate-Risk Pulmonary Embolism. New England Journal of Medicine, 370(15), 1402–1411. https://doi.org/10.1056/nejmoa1302097

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 450

59%

Researcher 186

24%

Professor / Associate Prof. 96

12%

Lecturer / Post doc 37

5%

Readers' Discipline

Tooltip

Medicine and Dentistry 924

93%

Agricultural and Biological Sciences 25

3%

Nursing and Health Professions 22

2%

Pharmacology, Toxicology and Pharmaceut... 21

2%

Article Metrics

Tooltip
Mentions
Blog Mentions: 1
News Mentions: 38
References: 1
Social Media
Shares, Likes & Comments: 288

Save time finding and organizing research with Mendeley

Sign up for free